Compounds > lamivudine
Page last updated: 2024-08-24

lamivudine and Disease Exacerbation

lamivudine has been researched along with Disease Exacerbation in 131 studies

Research

Studies (131)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's24 (18.32)18.2507
2000's65 (49.62)29.6817
2010's42 (32.06)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buzzetti, E; Davidson, BR; Gurusamy, KS; Mantzoukis, K; Rodríguez-Perálvarez, M; Thorburn, D; Tsochatzis, E1
Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY1
Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT1
Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N1
Al-Chalabi, A; Garcia Montojo, M; Gold, J; Kiernan, MC; Lombardi, V; Malaspina, A; Mathers, S; Mehta, PR; Nath, A; Norato, G; Rogers, ML; Rowe, DB; Santamaria, UA; van den Berg, LH; van Eijk, RPA; Vucic, S; Westeneng, HJ1
Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R1
Arase, Y; Ichida, T; Imazeki, F; Ito, K; Karino, Y; Kurosaki, M; Maeshiro, T; Masaki, N; Michitaka, K; Mita, E; Mizokami, M; Murata, K; Saito, T; Sugiyama, M; Takikawa, Y; Tanaka, Y; Tanuma, J; Toyoda, H; Umemura, T; Yamamoto, K; Yatsuhashi, H; Yoneda, M; Yotsuyanagi, H1
Abdallah, HB; Abdelli, MN; Bouali, R; El Kossai, I; Haddad, W; Haloues, M; Harzallah, K; Hmida, J; Manaa, J; Romdhane, NB1
Ahn, SH; Hahn, KY; Han, KH; Kim, BK; Kim, DY; Kim, HC; Kim, JK; Kim, SU; Park, JY; Park, YH; Shin, SH1
Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL1
Deng, YR; Jin, QL; Lian, ZX; Matsuzaki, K; Moritoki, Y; Murata, M; Niu, JQ; Tsuneyama, K; Yamaguchi, T; Yoshida, K1
Borok, M; Campbell, TB; Erlandson, KM; Fiorillo, S; Gudza, I; Gwanzura, L; Ndemera, B; Schooley, RT1
Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB1
Chen, EQ; Tang, H1
Bao, S; Cai, W; Guo, Q; Lin, L; Liu, Y; Wang, H; Wu, S; Xie, Q; Xu, B; Xu, G; Zhou, X; Zhuang, Y1
Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT1
Bierman, W; Bravenboer, B; Gisolf, E; Groeneveld, P; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, Ts; Vriesendorp, R1
Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D1
Donnen, P; Koy, T; Malandala, GL; Mukumbi, H; Wilmet-Dramaix, M1
Boettler, T; Thimme, R1
Kowdley, K; Sundaram, V1
Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R1
Anzai, K; Arase, Y; Hirose, S; Kagawa, T; Mine, T; Nagata, N; Shiraishi, K; Tsuruya, K1
Adler, H; Boon, G; Carty, C; Goldswain, C; Harper, K; Jackson, V; Lambert, JS; Linder, V1
Cho, YK; Choi, KY; Jeon, WK; Jung, YS; Kim, BI; Kim, HJ; Park, DI; Park, JH; Park, SK; Sohn, CI; Yang, HJ1
Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Sata, M; Takao, Y; Tanaka, K1
Babiker, AG; Cotton, MF; Gibb, DM; Jean-Philippe, P; Madhi, SA; McIntyre, JA; Steyn, J; Violari, A1
Liaw, YF1
Arnold, E; Cook, G; Iloeje, U; Yuan, Y1
Black, V; Guidozzi, F1
Locarnini, S; Warner, N1
Buffet, C1
Kao, JH; Lim, SG; Mohammed, R; Yuen, MF1
Ahn, SH; Chang, HY; Han, KH; Kim, DY; Kim, JK; Lee, CK; Lee, JM; Lee, KS; Park, JY; Park, YK1
Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E1
Babiker, AG; Darbyshire, JH; Gibb, DM; Gilks, CF; Grosskurth, H; Kityo, C; Mugyenyi, P; Munderi, P; Reid, A; Ssali, F; Walker, AS1
Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J1
Bella, MR; Casas Rodrigo, M; Dalmau Obrador, B; Gil Prades, M; Miquel Planas, M; Puig Domingo, J; Sanchez Delgado, J; Vergara Gómez, M1
Arisawa, T; Hayashi, R; Nomura, T; Sato, K; Shiroeda, H; Tsutsumi, M; Yamada, M1
Mallet, V; Pol, S; Vallet-Pichard, A1
Ahn, JS; Choi, MS; Gwak, GY; Im, YH; Kang, ES; Kim, KH; Lee, JE; Nam, SJ; Park, YH; Yang, JH; Yun, J1
Kojima, S; Mine, T; Motegi, S; Nishizaki, Y; Shiozawa, H; Watanabe, N1
Arcaini, L; Bruno, R; Lucioni, M; Merli, M; Paulli, M; Rattotti, S; Riboni, R; Vercelli, A1
Furusyo, N; Hayashi, J; Murata, M; Ogawa, E; Ohnishi, H; Taniai, H; Toyoda, K; Unno, M1
Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D1
Arai, M; Fujiwara, K; Goto, N; Imazeki, F; Kamezaki, H; Kanda, T; Nakamoto, S; Shinozaki, M; Wu, S; Yokosuka, O1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mori, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Naggie, S; Sulkowski, MS1
Han, Y; Li, T; Li, Y; Wang, H; Zhang, C; Zhang, X; Zhu, T1
Ankcorn, M; Appiah, L; Chadwick, D; Foster, G; Geretti, AM; Phillips, R; Sarfo, S; Schwab, U; Stanley, A1
Angus, PW1
Mano, Y; Shimosegawa, T; Ueno, Y; Yahagi, K1
Dienstag, JL; Gardner, S; Goldin, RD; Gray, DF; Hann, HW; Heathcote, EJ; Schiff, ER; Stephenson, SL; Woessner, M1
Fontana, RJ1
Jacobson, IM; Purow, DB1
Katano, H; Kimura, S; Niino, H; Oka, S; Teruya, K; Yamamoto, Y; Yasuoka, A1
Kirchner, JT; Lin, KW1
Bonino, F; Brunetto, MR; Casazza, G; Favre, C; Macchia, P; Menconi, MC; Nardi, M; Oliveri, F1
Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA1
Inoue, O; Mawatari, H; Nakagawa, Y1
Chow, WC; Dixon, JS; Farrell, G; Gray, DF; Keene, ON; Lee, CZ; Liaw, YF; Sabbat, J; Shue, K; Sung, JJ; Tanwandee, T; Tao, QM; Yuen, H1
Wands, JR1
Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A1
Colombo, M; Donato, MF1
Guan, R1
Gane, E1
Chen, JY; Gong, ZJ; Sun, XM; Wang, LW1
Karayiannis, P; Thomas, HC1
Bernard, M; Bouhour, D; Boulliat, J; Fleury, J; Laurent-Coriat, C; Tilikete, C; Vighetto, A1
Alberti, A; Buti, M; Cooksley, WG; Fried, MW; Gish, RG; Hadziyannis, SJ; Keeffe, EB; Liaw, YF; Naoumov, NV; Perrillo, RP; Peters, M; Schalm, S; Schiff, ER; Thio, CL; Tsai, N1
Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Scherpbier, HJ; van Leth, F1
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J1
Akarca, US; Cakaloglu, Y; de Man, RA; Flink, HJ; Janssen, HL; Schalm, SW; Simon, C; So, TM; van Zonneveld, M; Zondervan, PE1
Jung, JO; Kim, BG; Kim, YJ; Lee, HS; Yoon, JH1
Bowornkitikajorn, P; Chearskul, S; Chokephaibulkit, K; Chotpitayasunondh, T; Phongsamart, W; Samkoset, R; Sutthent, R; Tarunothai, U; Vanprapar, N1
Berg, T; Feucht, HH; Hüppe, D; Möller, B; Sarrazin, C; Spengler, U; van Bömmel, F; Wiedenmann, B; Zöllner, B1
Haché, C; Villeneuve, JP1
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Iwasaki, S; Kobayashi, M; Kumada, H; Miyakawa, Y; Sato, J; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S1
Abdul, HM; Ansari, MA; Butterfield, DA; Nath, A; Opii, WO; Sultana, R1
Desai, VG; Fuscoe, JC1
Aoyagi, T; Aoyagi, Y; Ichida, T; Nomoto, M; Ohkoshi, S; Osaki, A; Takamura, M; Terada, H; Tsubata, S; Uehara, K1
Arora, G; Keeffe, EB1
Piao, DM; Piao, XX; Ren, FY1
Chang, TT; Chen, PJ; Chuang, WL; Patel, K; Sullivan, SD; Tsai, C; Veenstra, DL1
Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Tsai, JF; Wang, LY; Yu, ML1
Ananworanich, J; Bunupuradah, T; Leng, LK; Pancharoen, C; Sosothikul, D; Thisyakorn, U; Trinavarat, P1
Clarke, L; Di Bisceglie, A; Gish, RG; Iloeje, UH; Kowdley, KV; Sullivan, SD; Tafesse, E; Veenstra, DL1
Bzowej, NH; Han, SH; Ishitani, MB; Lok, AS; Osborn, MK; Regev, A; Tran, TT1
Colombo, M; Iavarone, M; Lampertico, P; Manenti, E; Sablon, E; Viganò, M1
Keeffe, EB1
Chow, DH; Fung, J; Lai, CL; Ngai, VW; Seto, WK; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF1
Jia, JD1
Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J1
Balis, F; Brouwers, P; Church, J; Farley, M; Goldsmith, J; Keller, A; Lewis, LL; Mueller, B; Pizzo, PA; Rubin, M; Shearer, GM; Sloas, M; Venzon, D; Wheeler, S; Wood, L; Yuen, G1
Bartlett, JA; Eron, JJ; Hill, AM; Johnson, J; Phillips, AN; Price, S; Rubin, M; Self, P1
Bartlett, J; Eron, JJ; Hill, AM; Johnson, J; Katlama, C; McDade, H; Sawyer, W; Staszewski, S1
Balfour, HH; Chodakewitz, JA; Currier, JS; Demeter, LM; Deyton, LR; Eron, JJ; Feinberg, JE; Fischl, MA; Grimes, JM; Hammer, SM; Hughes, MD; Squires, KE1
Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S1
DeMasi, R; Hill, AM; Montaner, JS1
Belohradsky, BH; Eberle, J; Gürtler, L; Hoffmann, F; Notheis, G; Petropoulou, T; Sölder, B; Wintergerst, U1
Cammack, N; Dalgleish, AG; Sharland, M; Watkins, AM; Westby, M1
Brouwers, P; Johnson, GM; Keller, A; McKinney, RE; McNamara, J; Mitchell, WG; Mofenson, L; O'Donnell, KJ; Spector, SA; Stanley, K; Wara, DW; Wiznia, A; Yogev, R; Yong, FH1
Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B1
Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S1
Bucy, RP; Gnann, JW; Goepfert, PA; Kilby, JM; Miller, AP; Saag, MS; Sillers, M1
Carter, LM; Ellis, BA; Peters, BS; Wolstencroft, RA1
Church, JA; Cutrell, A; Emmanuel, P; Hetherington, S; Mitchell, C; Nelson, RP; Richardson, CG; Sáez-Llorens, X; Sleasman, J; Spreen, W; Van Dyke, R; Wiznia, A1
Regev, A; Schiff, ER1
Loveday, C1
James, JS2
Randall, P1
Doepel, L; Folkers, G1
Coppedge, B1
Gilden, D1
Asjö, B; Berg, OG; Dyrhol-Riise, AM; Kleivbo, S; Olofsson, J; Voltersvik, P1
Brooks, EA; Lacey, LF; Miller, DW; Payne, SL1
Chizzolini, C; Deléaval, P; Descombes, E; Hecker, E; Nicole, A; Pugin, P; Regamey, C; Schrago, G; Stadler, P1
Chadapaud, S; Halfon, P; Hittinger, G; Khiri, H; Lafeuillade, A; Poggi, C1
Leung, N1
Bosch, RJ; Coombs, RW; Demeter, LM; Fischl, MA; Fiscus, SA; Grimes, JM; Hammer, SM; Hughes, MD; Jackson, JB; Spector, SA; Squires, KE1
Ramrakhiani, S; Sponseller, CA1
Crowley, S; Desmond, P; Lees, M; Saal, G; Tognarini, D1

Reviews

25 review(s) available for lamivudine and Disease Exacerbation

ArticleYear
Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.
    The Cochrane database of systematic reviews, 2017, Mar-21, Volume: 3

    Topics: Acute Disease; Antiviral Agents; Disease Progression; Guanine; Hepatic Encephalopathy; Hepatitis B; Hepatitis C, Chronic; Humans; Immunization, Passive; Interferons; Lamivudine; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors

2017
Optimization therapy for the treatment of chronic hepatitis B.
    World journal of gastroenterology, 2014, May-21, Volume: 20, Issue:19

    Topics: Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunologic Factors; Interferons; Lamivudine; Precision Medicine; Treatment Outcome; Viral Load

2014
Management of chronic hepatitis B infection.
    BMJ (Clinical research ed.), 2015, Oct-21, Volume: 351

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunization Programs; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Viral Load

2015
Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29 Suppl 1

    Topics: Age Factors; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome

2009
[Chronic hepatitis B: current therapy].
    Bulletin de l'Academie nationale de medecine, 2008, Volume: 192, Issue:8

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome

2008
Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Antiviral Agents; Asia; Carcinoma, Hepatocellular; Child; Child, Preschool; Disease Progression; DNA, Viral; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization Programs; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Time Factors; Treatment Outcome; Viral Load; Young Adult

2009
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom

2010
[Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:8

    Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Doxorubicin; Fatal Outcome; Hepatectomy; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Magnetic Resonance Imaging; Male; Ultrasonography; Viral Load

2010
The impact of human immunodeficiency virus on viral hepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine

2011
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome

2012
Management of patients with decompensated HBV cirrhosis.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors

2003
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications.
    Postgraduate medicine, 2003, Volume: 114, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Child; Disease Progression; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Treatment Outcome

2003
Hepatitis B.
    American family physician, 2004, Jan-01, Volume: 69, Issue:1

    Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Hepatitis B; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Patient Selection; Recombinant Proteins; Reverse Transcriptase Inhibitors; Risk Factors; Sexually Transmitted Diseases; Substance Abuse, Intravenous; United States; Vaccination

2004
[Introduction to chronic hepatitis type B].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 8

    Topics: Age Factors; Amino Acid Motifs; Antiviral Agents; Disease Progression; Genotype; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver; Liver Cirrhosis; Mutation

2004
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir

2005
Prevention of hepatocellular carcinoma.
    Seminars in liver disease, 2005, Volume: 25, Issue:2

    Topics: Carcinoma, Hepatocellular; Chemoprevention; Disease Progression; Disease Susceptibility; Hepatitis B; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Reverse Transcriptase Inhibitors; Secondary Prevention; Vaccination

2005
Treatment of chronic hepatitis B in HIV co-infected patients.
    The Medical journal of Malaysia, 2005, Volume: 60 Suppl B

    Topics: Antiretroviral Therapy, Highly Active; Comorbidity; Disease Progression; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Recurrence; Reverse Transcriptase Inhibitors; Risk Factors

2005
Liver transplantation in chronic hepatitis B.
    The Medical journal of Malaysia, 2005, Volume: 60 Suppl B

    Topics: Chemoprevention; Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors; Secondary Prevention

2005
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:13

    Topics: Disease Progression; Drug-Related Side Effects and Adverse Reactions; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis

2006
Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
    Reviews in gastroenterological disorders, 2007,Spring, Volume: 7, Issue:2

    Topics: Adenine; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Organophosphonates

2007
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
    AIDS (London, England), 1997, Mar-15, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; United States; Zidovudine

1997
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
    Annals of internal medicine, 2000, Sep-19, Volume: 133, Issue:6

    Topics: Acute Disease; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chronic Disease; Disease Progression; Drug Therapy, Combination; Fever; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Syndrome; Viral Load; Zidovudine

2000
Drug therapy for hepatitis B.
    Advances in internal medicine, 2001, Volume: 46

    Topics: Adenine; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Male; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors

2001
International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
    Journal of acquired immune deficiency syndromes (1999), 2001, Mar-01, Volume: 26 Suppl 1

    Topics: Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine

2001
Treatment of hepatitis B and C following liver transplantation.
    Current gastroenterology reports, 2002, Volume: 4, Issue:1

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Interferon-alpha; Lamivudine; Liver Transplantation; Organophosphonates; Prognosis; Ribavirin; Secondary Prevention; Survival Rate

2002

Trials

34 trial(s) available for lamivudine and Disease Exacerbation

ArticleYear
Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 24

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Herpesvirus 8, Human; HIV-1; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; RNA, Viral; Sarcoma, Kaposi; Survival Analysis; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Zidovudine; Zimbabwe

2014
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
    Nutrients, 2014, Nov-13, Volume: 6, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine

2014
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    HIV medicine, 2015, Volume: 16, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Belgium; CD4 Lymphocyte Count; Clinical Protocols; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Netherlands; Prospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine

2015
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult

2016
Early antiretroviral therapy and mortality among HIV-infected infants.
    The New England journal of medicine, 2008, Nov-20, Volume: 359, Issue:21

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Failure; Zidovudine

2008
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine

2010
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    HIV medicine, 2010, Volume: 11, Issue:5

    Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Uganda; Viral Load; Zidovudine

2010
Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
    Journal of clinical gastroenterology, 2011, Volume: 45, Issue:9

    Topics: Adenine; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome

2011
Histological outcome during long-term lamivudine therapy.
    Gastroenterology, 2003, Volume: 124, Issue:1

    Topics: Adult; Alanine Transaminase; Disease Progression; DNA, Viral; Drug Administration Schedule; Female; Genetic Variation; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Necrosis; Reverse Transcriptase Inhibitors; Safety

2003
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Aug-01, Volume: 39, Issue:3

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine

2004
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
    The New England journal of medicine, 2004, Oct-07, Volume: 351, Issue:15

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Drug Resistance; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Severity of Illness Index

2004
Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?
    Nature clinical practice. Gastroenterology & hepatology, 2005, Volume: 2, Issue:3

    Topics: Biopsy; Disease Progression; Double-Blind Method; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Ultrasonography

2005
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
    Revista clinica espanola, 2006, Volume: 206, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Disease Progression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine; Zidovudine

2006
Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:4

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Necrosis; Polyethylene Glycols; Recombinant Proteins

2006
High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.
    Journal of gastroenterology, 2006, Volume: 41, Issue:3

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Bilirubin; Biomarkers; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Korea; Lamivudine; Liver Failure; Male; Middle Aged; Multivariate Analysis; Mutation; Platelet Count; Predictive Value of Tests; Prospective Studies; Prothrombin Time; Reverse Transcriptase Inhibitors; Risk Factors; Serum Albumin

2006
Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: a multi-center study in Thailand 1998-2000.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88 Suppl 8

    Topics: Developing Countries; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine

2005
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Journal of medical virology, 2006, Volume: 78, Issue:10

    Topics: Administration, Oral; Adolescent; Adult; Aged; Disease Progression; Female; Genetic Markers; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Hospitals, Urban; Humans; Lamivudine; Male; Middle Aged; Mutation; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Time Factors; Tokyo; Treatment Outcome

2006
A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.
    World journal of gastroenterology, 2007, Aug-21, Volume: 13, Issue:31

    Topics: Adult; Aged; Antiviral Agents; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Virus Replication

2007
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    PharmacoEconomics, 2007, Volume: 25, Issue:11

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Quality of Life; Salvage Therapy

2007
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Gastroenterology, 2007, Volume: 133, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Risk Factors; Survival Analysis; Treatment Outcome

2007
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Antiviral therapy, 2007, Volume: 12, Issue:8

    Topics: Adult; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome

2007
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:5

    Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Biopterins; CD4 Lymphocyte Count; Disease Progression; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neopterin; Zalcitabine

1995
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
    The Journal of infectious diseases, 1996, Volume: 174, Issue:1

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Lamivudine; Male; Pancreatitis; Risk Factors; RNA, Viral; Treatment Outcome; Zalcitabine

1996
HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
    AIDS (London, England), 1996, Volume: 10, Issue:8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Predictive Value of Tests; Proportional Hazards Models; RNA, Viral; Zidovudine

1996
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
    AIDS (London, England), 1997, Mar-15, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; United States; Zidovudine

1997
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet (London, England), 1997, May-17, Volume: 349, Issue:9063

    Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine

1997
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    The New England journal of medicine, 1997, Sep-11, Volume: 337, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Zidovudine

1997
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    AIDS (London, England), 1998, Mar-26, Volume: 12, Issue:5

    Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine

1998
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    The Journal of pediatrics, 1998, Volume: 133, Issue:4

    Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; Child; Child, Preschool; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Neurodegenerative Diseases; Polymerase Chain Reaction; RNA, Viral; Survival Rate; Zidovudine

1998
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
    The Journal of infectious diseases, 1999, Volume: 180, Issue:3

    Topics: Acetamides; Acetophenones; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Disease Progression; Disease-Free Survival; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Placebos; Retrospective Studies; Time Factors

1999
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Pediatrics, 2001, Volume: 107, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Growth; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Zidovudine

2001
Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    The American journal of managed care, 2001, Volume: 7, Issue:7

    Topics: Antiviral Agents; Budgets; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; United States

2001
Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
    Journal of acquired immune deficiency syndromes (1999), 2001, Oct-01, Volume: 28, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Morbidity; Prognosis; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine

2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Annals of internal medicine, 2001, Dec-04, Volume: 135, Issue:11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Logistic Models; Male; Middle Aged; RNA, Viral; Viral Load; Zidovudine

2001

Other Studies

73 other study(ies) available for lamivudine and Disease Exacerbation

ArticleYear
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2

    Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome

2018
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
    Journal of medical case reports, 2018, Feb-28, Volume: 12, Issue:1

    Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Medication Adherence; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tacrolimus

2018
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:8

    Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load

2019
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 20, Issue:7-8

    Topics: Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Cohort Studies; Dideoxynucleosides; Disease Progression; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult

2019
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load

2013
Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:1

    Topics: Adult; Antiviral Agents; Cohort Studies; Disease Progression; Female; Genotype; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Japan; Lamivudine; Male; Middle Aged; Risk Factors; Time Factors; Young Adult

2014
Pre-emptive treatment of hepatitis B infection by lamivudine in two Tunisian renal transplant recipients.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2013, Volume: 24, Issue:6

    Topics: Adult; Disease Progression; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Kidney Transplantation; Lamivudine; Male; Reverse Transcriptase Inhibitors; Tunisia

2013
Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Telbivudine; Thymidine; Time Factors; Treatment Outcome

2014
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
    Revista de saude publica, 2013, Volume: 47, Issue:4

    Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome

2013
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
    Clinical and experimental immunology, 2014, Volume: 176, Issue:1

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunohistochemistry; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Phosphorylation; Protein Isoforms; Signal Transduction; Smad3 Protein; Telbivudine; Thymidine; Treatment Outcome; Young Adult

2014
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine

2014
Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:2

    Topics: Adult; Antiviral Agents; Biomarkers; Biopsy; Disease Progression; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors

2015
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:8

    Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome

2015
[Comparative and evolutionary profile of people infected with HIV on antiretroviral therapy in Kinshasa, Democratic Republic of Congo].
    The Pan African medical journal, 2014, Volume: 19

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Democratic Republic of the Congo; Disease Progression; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Zidovudine

2014
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir

2015
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
    BMC gastroenterology, 2016, Mar-17, Volume: 16

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load

2016
Lamivudine Monotherapy: Experience of Medium-term Outcomes in HIV-infected Children Unable to Adhere to Triple Therapy.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:7

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Medication Adherence; Retrospective Studies; South Africa; Treatment Outcome; Young Adult

2016
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:3

    Topics: Adenine; Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Treatment Outcome

2016
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:11

    Topics: Adenine; Adult; Antiviral Agents; Bilirubin; Disease Progression; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Patient Selection; Predictive Value of Tests; Prognosis; Prothrombin Time; Retrospective Studies; Treatment Outcome

2008
Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Applied health economics and health policy, 2008, Volume: 6, Issue:4

    Topics: Absenteeism; Analysis of Variance; Anti-HIV Agents; Australia; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Forecasting; Guanine; Health Care Costs; Health Services Research; Hepatitis B, Chronic; Humans; Lamivudine; Life Expectancy; Models, Econometric; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Treatment Outcome; Value of Life

2008
The obstetric face and challenge of HIV/AIDS.
    Clinical obstetrics and gynecology, 2009, Volume: 52, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Developing Countries; Disease Progression; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Maternal Mortality; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Trimethoprim, Sulfamethoxazole Drug Combination; World Health Organization; Zidovudine

2009
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates

2009
Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:7

    Topics: Adult; Analysis of Variance; Case-Control Studies; Confidence Intervals; Disease Progression; Female; Follow-Up Studies; Gene Expression Regulation; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polymorphism, Genetic; Probability; Promoter Regions, Genetic; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2010
Accelerated progression of hepatocellular carcinoma with cytokeratin 19 expression during treatment with lamivudine for hepatitis B virus-related liver cirrhosis.
    Scandinavian journal of gastroenterology, 2011, Volume: 46, Issue:2

    Topics: Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hepatitis B virus; Humans; Keratin-19; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged

2011
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
    British journal of cancer, 2011, Feb-15, Volume: 104, Issue:4

    Topics: Adult; Aged; Algorithms; Anthracyclines; Antibiotic Prophylaxis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Carcinoma; Case-Control Studies; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Female; Hepatitis B; Humans; Incidence; Lamivudine; Middle Aged; Postoperative Complications; Retrospective Studies

2011
Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B.
    The Tokai journal of experimental and clinical medicine, 2010, Sep-20, Volume: 35, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Disease Progression; Female; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Treatment Failure; Viral Load

2010
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Antiviral Agents; Asymptomatic Diseases; Bone Marrow; Carrier State; Cell Transformation, Viral; Disease Progression; Female; Genes, bcl-2; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Lymphoma, B-Cell; Lymphoma, Follicular; Middle Aged; Neoplasm, Residual; Remission Induction; Splenic Neoplasms

2011
Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.
    World journal of gastroenterology, 2011, Jun-28, Volume: 17, Issue:24

    Topics: Adult; Aged; Asian People; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Time

2011
Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.
    International journal of medical sciences, 2012, Volume: 9, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors

2012
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.
    Journal of gastroenterology, 2012, Volume: 47, Issue:9

    Topics: Adult; Alanine Transaminase; Bilirubin; Disease Progression; Disseminated Intravascular Coagulation; DNA, Viral; Female; Glucocorticoids; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Jaundice; Lamivudine; Male; Middle Aged; Prognosis; Prospective Studies; Prothrombin; Treatment Outcome; Viral Load; Young Adult

2012
Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.
    AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14

    Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult

2012
Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.
    AIDS (London, England), 2013, Jan-02, Volume: 27, Issue:1

    Topics: Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Ghana; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load

2013
Hepatitis B: weighing the costs of treatment.
    Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:7

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Hepatitis B; Hepatitis B virus; Humans; Interferon Type I; Lamivudine; Life Expectancy; Recombinant Proteins

2002
Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:12

    Topics: Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Reverse Transcriptase Inhibitors; Rhabdomyolysis; Waiting Lists

2002
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Disease Progression; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Gastrointestinal Neoplasms; Herpesviridae Infections; Herpesvirus 4, Human; Herpesvirus 8, Human; HIV-1; Humans; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prednisone; Ritonavir; Saquinavir; Sarcoma, Kaposi; Skin Neoplasms; Stavudine; Tumor Virus Infections; Vincristine

2003
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer.
    Bone marrow transplantation, 2004, Volume: 33, Issue:10

    Topics: Adoptive Transfer; Animals; Antilymphocyte Serum; Antiviral Agents; Bone Marrow Transplantation; Child; Disease Progression; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Heterozygote; Histocompatibility Testing; Horses; Humans; Immunotherapy, Adoptive; Lamivudine; Liver; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Tissue Donors

2004
Prevention of hepatocellular carcinoma.
    The New England journal of medicine, 2004, Oct-07, Volume: 351, Issue:15

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Mutation; Virus Replication

2004
Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:3

    Topics: Acute Disease; Administration, Oral; Adult; Bilirubin; Biomarkers; Disease Progression; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Failure, Acute; Male; Middle Aged; Prognosis; Radiography; Recurrence; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Transaminases; Treatment Outcome; Ultrasonography

2005
Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2005, Volume: 4, Issue:3

    Topics: Adult; Amino Acid Sequence; Antiviral Agents; Base Sequence; Disease Progression; Female; Genetic Variation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Severity of Illness Index

2005
[HIV infection presenting with bilateral optic neuropathy].
    Revue neurologique, 2006, Volume: 162, Issue:1

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Facial Nerve Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ischemia; Lamivudine; Lopinavir; Male; Meningitis, Viral; Methylprednisolone; Middle Aged; Optic Disk; Optic Nerve Diseases; Polyradiculopathy; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Visual Fields; Zidovudine

2006
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Biopsy; Clinical Competence; Disease Progression; DNA, Viral; Drug Therapy, Combination; Endpoint Determination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver; Organophosphonates; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Societies, Medical; Virus Replication

2006
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
    Pediatrics, 2006, Volume: 117, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure

2006
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:2

    Topics: Adenine; Adult; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication

2006
Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.
    Experimental neurology, 2007, Volume: 204, Issue:1

    Topics: AIDS Dementia Complex; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bridged-Ring Compounds; Caspase 3; Cerebral Cortex; Cytochromes c; Disease Progression; Gerbillinae; Humans; Lamivudine; Male; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Norbornanes; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Synaptosomes; Thiocarbamates; Thiones; Tyrosine; Zalcitabine

2007
Transcriptional profiling for understanding the basis of mitochondrial involvement in disease and toxicity using the mitochondria-specific MitoChip.
    Mutation research, 2007, Mar-01, Volume: 616, Issue:1-2

    Topics: Animals; Disease Progression; DNA, Mitochondrial; Female; Gene Expression Profiling; Lamivudine; Mice; Mitochondria; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Inhibitors; Zidovudine

2007
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:7

    Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Viral; Follow-Up Studies; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lamivudine; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Risk Assessment; Severity of Illness Index; Treatment Outcome

2007
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:9

    Topics: Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Markov Chains; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Taiwan

2007
Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome

2007
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:9

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Progression; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Remission, Spontaneous; Spinal Neoplasms; Stavudine; Time Factors

2007
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:12

    Topics: Disease Progression; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; United States; Waiting Lists

2007
Hepatitis B: explosion of new knowledge.
    Gastroenterology, 2007, Volume: 133, Issue:5

    Topics: Adenine; Antiviral Agents; Disease Progression; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Lamivudine; Organophosphonates

2007
Antiviral therapy for various stages of HBV-related diseases: lamivudine and beyond.
    Journal of gastroenterology and hepatology, 2008, Volume: 23, Issue:5

    Topics: Antiviral Agents; Disease Progression; Hepatitis B, Chronic; Humans; Lamivudine

2008
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1998, Mar-01, Volume: 17, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine

1998
Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
    The Pediatric infectious disease journal, 1998, Volume: 17, Issue:6

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viral Load; Zidovudine

1998
Immune reconstitution in HAART-treated children with AIDS. Highly Active Anti-Retroviral Therapy.
    Lancet (London, England), 1998, Aug-15, Volume: 352, Issue:9127

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Child; Disease Progression; Female; Follow-Up Studies; Humans; Immunity, Cellular; Immunologic Memory; Lamivudine; Lymphocyte Count; Nelfinavir; Stavudine; Viral Load

1998
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    AIDS research and human retroviruses, 1999, Dec-10, Volume: 15, Issue:18

    Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine

1999
Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
    The Journal of infection, 2000, Volume: 41, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Lymphocytes; Macrophage Inflammatory Proteins; Male; Nelfinavir; Stavudine; Viral Load; Viremia

2000
Combination trials with 3TC/AZT stopped as clinical benefit shown.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:6

    Topics: Anti-HIV Agents; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic

1996
ACTG 320 trial halted as three-drug arm proves superior.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; United States; Zidovudine

1997
3TC: combination trial stopped early as clinical benefit shown.
    AIDS treatment news, 1996, Aug-02, Issue:no 252

    Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine

1996
3TC clinical benefit: more data presented.
    AIDS treatment news, 1996, Oct-04, Issue:No 256

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Disease Progression; Drug Therapy, Combination; Humans; Lamivudine; Male; Multicenter Studies as Topic

1996
Study shows three drugs better than two.
    AIDS alert, 1997, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Stavudine; United States; Zidovudine

1997
Study confirms that protease inhibitor cocktail can delay HIV disease progression and death.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; United States; Zidovudine

1997
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine

1997
ICAAC update.
    STEP perspective, 1996,Fall, Volume: 8, Issue:3

    Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load

1996
Spring cleaning in trial land.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1997, Volume: 11, Issue:3

    Topics: Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Stavudine; United States; Viral Load; Zidovudine

1997
Combo therapy for children and adolescents.
    Treatment review, 1997, Issue:No 25

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine

1997
Two drugs better than one for children.
    AIDS alert, 1997, Volume: 12, Issue:10

    Topics: Anti-HIV Agents; Child; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine

1997
Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    AIDS research and human retroviruses, 2001, May-01, Volume: 17, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Longitudinal Studies; Lymphoid Tissue; Phenotype; Proviruses; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Load; Viremia; Virus Replication; Zidovudine

2001
Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids.
    Clinical rheumatology, 2001, Volume: 20, Issue:4

    Topics: Adult; Combined Modality Therapy; Critical Illness; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Plasma Exchange; Polyarteritis Nodosa; Recombinant Proteins; Risk Assessment; Steroids; Treatment Outcome

2001
Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate?
    Journal of gastroenterology and hepatology, 2001, Volume: 16, Issue:9

    Topics: Carrier State; Disease Progression; Hepatitis B; Hepatitis B Surface Antigens; Humans; Lamivudine; Liver Function Tests; Organ Transplantation; Postoperative Complications; Survival Rate; Transplantation Immunology; Treatment Outcome; Virus Activation

2001
Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine.
    Annals of internal medicine, 2001, Dec-04, Volume: 135, Issue:11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; RNA, Viral; Viral Load; Zidovudine

2001
Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
    Journal of gastroenterology and hepatology, 2002, Volume: 17, Issue:2

    Topics: Antiviral Agents; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Health Care Costs; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Markov Chains; Models, Economic; Models, Statistical

2002